SAN FRANCISCO – Immune Design Corp. CEO Carlos Paya told attendees at the J.P. Morgan Healthcare Conference Thursday that the company is making solid progress toward what he believes is the future of in vivo cancer immunotherapy: combining the company's tumor-specific cytotoxic T cells (CTL)-boosting therapy CMB305 with a checkpoint inhibitor.